Markers such as CRP, AFP [34, 35], the CRAFITY score derived from CRP and AFP [36], and the neutrophil to lymphocyte ratio [37] have been reported as promising predictors of treatment benefit from immunotherapy in HCC. Here, CRP is linked to hepatocellular carcinoma.